[box type=”bio”] Learning Point of the Article: [/box]
Endoprosthetic reconstruction and limb salvage surgeries are feasible in fungating giant cell tumors of extremities provided oncological principles are adhered to.
Case Report | Volume 11 | Issue 2 | JOCR February 2021 | Page 19-23 | Namith Rangaswamy, Venkatesan Sampath Kumar, Roshan Banjara, Abdul Majeed, Devansh Goyal, Shah Alam Khan. DOI: 10.13107/jocr.2021.v11.i02.2008
Authors:Namith Rangaswamy, Venkatesan Sampath Kumar, Roshan Banjara, Abdul Majeed, Devansh Goyal, Shah Alam Khan
Department of Orthopedics, All India Institute of Medical Sciences, New Delhi, India.
Address of Correspondence:
Dr. Venkatesan Sampath Kumar,
Department of Orthopedics, All India Institute of Medical Sciences, New Delhi, India.
Introduction: The WHO defines giant cell tumor as a benign locally aggressive neoplasm with metastasizing capacity and aggressive behavior. Very rarely, these tumors are seen fungating, mostly when neglected. But when they do, the treatment option commonly conferred is amputation of the limb which is disabling and traumatizing.
Case Report: We report three cases of fungating limb masses (proximal tibia, distal fibula, and distal radius) diagnosed with giant cell tumor histologically, undergoing limb saving surgeries with various reconstruction techniques to endorse a good quality of life and functioning limb.
Conclusion: Our study is one of the earliest to report medium-term follow-up after such limb salvage procedure. We recommend that salvage procedures should be considered in giant cell tumors even in the presence of fungation if there is no neurovascular encasement.
Keywords: Giant cell tumor, fungation, limb salvage surgery, endoprosthesis, mesh reconstruction.
Giant cell tumors were described as early as in 1818 by Cooper and Travers . GCT constitutes about 5% of all bone tumors and 20% of benign bone tumors. Eighty percent of GCTs are found to occur between 20 and 50 years of age, having peak incidence at the 3rd decade and they uncommonly present with fungation. Microscopically, giant cell tumors are a blend of spindle-shaped stromal cells, multinucleated giant cells resembling osteoclasts, and mononuclear cells which are positive for CD-68 . GCT has a well-defined non-sclerotic margin located eccentrically in long bone extending close to the articular surface in patients with closed epiphysis seldom crossing the joint . Conventionally treatment of GCT included surgical curettage and PMMA (polymethylmethacrylate) cement application with or without adjuvant chemical ablation. Recent advances have shown that chemotherapeutic drugs such as denosumab have shown dramatic response with tumor necrosis in cases of early GCT . However, wide excision of the tumor is recommended in large or recurrent tumors. Radical amputation procedures are still a widely practiced treatment for massive tumors ulcerating the skin, leading to high morbidity and severe disability. Little or no literature of experience is available currently on limb salvage surgeries in such cases of fungating tumors. We report a series of three cases with fungating limb masses with histopathological diagnosis of giant cell tumor undergoing limb saving surgical procedures. Informed written consent was obtained from all the patients explaining the possibility of publication.
A 21-year-old female who presented to our outpatient clinic with complaints of pain and swelling in her left knee for 8 months before her first visit, with a sudden increase in size for later 2 months. On examination of her limb, there was gross wasting of quadriceps muscle with diffuse swelling over the lateral aspect of the distal thigh measuring approximately 12 cm long and 5 cm across. The local temperature was raised with tenderness on deep palpation restricting terminal knee flexion. On anteroposterior and lateral Roentgenogram, there was an eccentric lytic and sclerotic lesion in the left distal end femur with a narrow zone of transition without evidence of joint involvement, with some areas of soft-tissue calcification and minimal periosteal reaction. Core biopsy done reported to have cellular tissues with multinucleated osteoclast-like giant cells admixed with mononuclear cells, round to oval to spindle-shaped without significant cellular atypia and histological diagnosis of GCT was made.
The patient was lost to follow up, presented 3 months later with an enlarged mass measuring 15 cm x 12 cm with ulceration over the lateral aspect of the knee (Fig. 1). New AP and the lateral radiograph showed a large destructive lesion in the distal femur with chondroid matrix, broad zone of transition with break-in cortex, and destruction of joint margin, fresh magnetic resonance images showed a heterogeneous mass of the left distal femur with the erosion of joint margin extending about 15 cm from the joint line without involvement of femoral or popliteal vessels and nerves. CT scan of the chest was found to be normal. A final diagnosis of fungating non-metastatic giant cell tumor of the left distal femur, Campanacci Grade III with the left knee joint involvement was made.
Management options were explored, preferably to excise the tumor and reconstruct the limb to provide the functional ability, and the decision of wide excision with endoprosthesis application was made. Intraoperatively, careful dissection was done protecting the neurovascular bundle and the tumor was removed preventing any soft-tissue spillage. After confirmation of the safe margin through the frozen section examination, distal femoral endoprosthesis was cemented (Fig. 2). The post-operative specimen had features of GCT without atypia with safe bony and soft-tissue margins. The patient was put on protected weight-bearing initially, slowly progressing to full weight-bearing along with knee range of movement and quadriceps strengthening exercises. At follow-up of 2 years with extensive physical therapy, the patient has good functional results with flexion of 90° (Fig. 3) and is walking without pain enabling her to carry on comfortably with routine activities. No evidence of infection or local recurrence was seen.
A 28-year-old male patient presented with a bleeding mass from the left distal leg which developed following curettage elsewhere for a suspected giant cell tumor of the left distal fibula 1 year earlier. On examination, we found a mass of 8 × 8 cm with a large bleeding raw area over the lateral malleolus (Fig. 4). Imaging showed a lytic destructive lesion of distal fibula extending into the soft tissue on X-ray radiography (Fig. 5) with a substantiating picture on MRI. The diagnosis was confirmed by histopathological examination of biopsy specimen as GCT. The limb salvage procedure was done by wide resection of the tumor. Mesh repair was done to stabilize the ankle with screws placed in the distal tibia, talus, and calcaneum (Fig. 6). Below-knee slab was provided and gradual mobilization protocol was followed to get a successful mobile limb. No post-operative complication was encountered. At 1year follow-up, the patient can walk full weight-bearing unassisted with satisfactory ankle ROM (Fig. 7).
A 38-year-old male having a swelling in his left wrist for 3 years for which he was advised amputation below the level of his elbow elsewhere and that drew him to our institution. On presentation, physical examination revealed a dumbbell-shaped mass measuring 12 × 10 cm over his left wrist with extensively stretched skin and fungation over the dorsal surface (Fig. 8). Roentgenogram showed an expansile lytic lesion with soft-tissue extension over the distal radius with typical soap bubble appearance (Fig. 9) in concordance with MR imaging of heterogeneous T2W hyperintense lesion with an air-fluid level. The biopsy confirmed the diagnosis of GCT. Surgical intervention was done with careful resection of the tumor with meticulous dissection to save multiple encased tendons along with the centralization of the ulna with wrist arthrodesis plate to fuse the wrist joint and immobilized with a splint (Fig. 10a). Due to uncontrolled Type 2 diabetes mellitus, the patient developed deep surgical site infections in the early post-operative period. Plate removal with thorough surgical debridement was done and stabilized with K-wire (Fig. 10b) along with splinting. Adequate glycemic control with culture appropriate antibiotic was administered and healthy wound healing with successful arthrodesis was achieved to obtain a good functioning limb at the final follow-up of 1 year.
Giant cell tumor is a locally aggressive benign tumor  commonly involving the end of a long bone in young adults between 20 and 40 years of age with female predominance . Being a benign tumor, GCT can rarely be lethal, but is usually associated with the destruction of local bony architecture and can prove distressing due to periarticular locations. The ideal treatment solution is still debatable with a huge spectrum of surgical options available, the principle of treatment is to eradicate the tumor and preserve the function of a limb . However, even in current practice, radical procedures leading to the removal of limbs have been the main consensus of management in fungating, neglected, and large tumors. Neglected orthopedic malignancies have been a challenge to confront for surgeons worldwide. Some of the main reasons for patients to present in advanced stages are neglect by the patient and family, low socioeconomic status, unawareness, lack of access to medical facilities, and even misdiagnosis sometimes, leading to an enormous rise in morbidity and mortality . The experience of amputation can be traumatizing . Although there is a paucity of studies on quality of life following major limb amputation, Blåder et al. reported on 35 patients with malignant upper limb tumors who underwent amputation, half had to loose occupation affecting social life . The literature of experience on limb salvage procedures in fungating tumors of bone are very few and limited to case series, and none involve implantation of the endoprosthesis to provide a completely functional limb. Kamal et al. in his case report presented a case of 4 years lost to follow-up patient with a malignant giant cell tumor of the patella, presenting with an ulcerating lump over the left knee without the involvement of joint, for which complete excision of the tumor and reconstruction of extensor mechanism were done to obtain a mobile limb . Shrestha et al. presented a case of fungating giant cell tumor with the complete destruction of lower end ulna with the involvement of the wrist joint where the limb was saved by wide excision of the tumor with arthrodesis of the wrist joint . Chinder et al. recently published a case report on Ewing’s sarcoma of scapula presenting with fungation where they managed to salvage the limb . Fungating tumors make for 35% of cases undergoing amputation among orthopedic tumors . The decision to perform limb salvage surgery was taken in all the three patients in our report because the predominant neurovascular bundle was uninvolved by the tumor and the patients were unwilling for amputation. Since GCT is a benign tumor, even if the tumor has to recur locally in the soft tissues, it can be safely managed with wide excision without any increased risk of mortality. Amputation should be reserved and considered only when necessary to achieve palliation of debilitating symptoms as it results in severe disability of function, hugely affecting the livelihood and quality of life.
The primary concern in the management of fungating tumors is the fear of infection. Our patients managed with endoprosthetic reconstruction and synthetic mesh reconstruction had no signs of post-operative infection. However, a diabetic patient who underwent arthrodesis developed surgical site infection requiring debridement and resurgery. Hence, we believe systemic factors together with the local nature of the disease contribute to the successful outcome of the management. Therefore, fungation should not be the sole deciding element for amputation.
Secondary erosive arthritis of knee as a rare presentation of PAPS must be kept in mind and its treatment involves multidisciplinary approach for its effective management.
1. Palomo I, Segovia F, Ortega C, Pierangeli S. Antiphospholipid syndrome: A comprehensive review of a complex and multisystemic disease. Clin Exp Rheumatol 2009;27:668-77.
2. Harris EN, Pierangeli SS. Primary, secondary, catastrophic antiphospholipid syndrome: Is there a difference? Thromb Res 2004;114:357-61.
3. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1, 000 patients. Arthritis Rheum 2002;46:1019-27.
4. Noureldine MH, Khamashta MA, Merashli M, Sabbouh T, Hughes GR, Uthman I. Musculoskeletal manifestations of the antiphospholipid syndrome. Lupus 2016;25:451-62.
5. Vasoo S, Sangle S, Zain M, D’Cruz D, Hughes G. Orthopaedic manifestations of the antiphospholipid (Hughes) syndrome. Lupus 2005;14:339-45.
6. Rueda JC, Duque MA, Mantilla RD, Iglesias-Gamarra A. Osteonecrosis and antiphospholipid syndrome. J Clin Rheumatol 2009;15:130-2.
7. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16:494-502.
8. Wilson W, Gharavi A, Koike T, Lockshin MD, Branch DW, Piette JC, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an international workshop. Arthritis Rheum 1999;42:1309-11.
9. Miyakis S, Lockshin M, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
10. Rostom S, Bahiri R, Hajjaj-Hassouni N. Multifocal avascular necrosis revealing antiphospholipid syndrome. Clin Rheumatol 2008;27:271-2.
11. Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019;78:1296-304.
12. Saunders KH, Erkan D, Lockshin MD. Perioperative management of antiphospholipid antibody-positive patients. Curr Rheumatol Rep 2014;16:426.
13. Erkan D, Lockshin M. New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol 2009;5:160-70.
14. Fischetti F, Durigutto P, Pellis V, Debeus A, Macor P, Bulla R, et al. Thrombus formation induced by antibodies to beta 2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005;106:2340-6.
15. Asherson RA, Cervera R, Piette JC, Shoenfeld Y, Espinosa G, Petri MA, et al. Catastrophic antiphospholipid syndrome: Clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001;80:355-76.
16. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients. Lupus 2011;20:206-18.
17. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med 2018;378:2010-21.
18. Chouhan VD, Comerota AJ, Sun L, Harada R, Gaughan JP, Rao AK. Inhibition of tissue factor pathway during intermittent pneumatic compression: A possible mechanism for antithrombotic effect. Arterioscler Thromb Vasc Biol 1999;19:2812-7.
19. Kakkos SK, Caprini JA, Geroulakos G, Nicolaides AN, Stansby GP, Reddy DJ. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism in high-risk patients. Cochrane Database Syst Rev 2008;4:CD005258.
20. Erkan D, Leibowitz E, Berman J, Lockshin MD. Perioperative medical management of antiphospholipid syndrome: Hospital for special surgery experience, review of literature, and recommendations. J Rheumatol 2002;29:843-9.
|Dr. Namith Rangaswamy||Dr. Venkatesan Sampath Kumar||Dr. Roshan Banjara||Dr. Devansh Goyal||Dr. Shah Alam Khan|
|How to Cite This Article: Muthu S, Chellamuthu G, Gopalsamy TP, Kandasamy V. Secondary Erosive Arthritis in a Young Lady – A Rare Manifestation of Primary Antiphospholipid Antibody Syndrome. Journal of Orthopaedic Case Reports 2021 February;11(2): 19-23.|
[Full Text HTML] [Full Text PDF] [XML]
Dear Reader, We are very excited about New Features in JOCR. Please do let us know what you think by Clicking on the Sliding “Feedback Form” button on the <<< left of the page or sending a mail to us at firstname.lastname@example.org